Notebook

The World Health Organization (WHO), based in Geneva, will back large-scale clinical trials of two experimental HIV vaccines that failed earlier this year to win similar approval in the United States. In June, Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), chose not to support the complex and costly trials because "the science wasn't there to justify it." Each vaccine relies on stimul

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The World Health Organization (WHO), based in Geneva, will back large-scale clinical trials of two experimental HIV vaccines that failed earlier this year to win similar approval in the United States. In June, Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), chose not to support the complex and costly trials because "the science wasn't there to justify it." Each vaccine relies on stimulating an immune response to the surface protein gp120 on the virus thought to cause AIDS. Apparently, the international health organization looked at the same data Fauci did, from smaller trials in humans, and saw sufficient immune system improvement demonstrated to warrant further studies. "The World Health Organization, in contrast to the NIAID, has decided to go ahead and test these vaccines in efficacy trials and put their blessing on that," says Don Francis, the clinical scientist managing the trials for Genentech. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies